@conference{325007ef4f6844dea09413a8b5911f61,
title = "Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.",
author = "Martin Gutierrez and Long, \{Georgina V.\} and Friedman, \{Claire Frances\} and Richards, \{Donald A.\} and Bradley Corr and Bastos, \{Bruno R.\} and Uemura, \{Marc Isamu\} and Conkling, \{Paul R.\} and Victor Moreno and Edenfield, \{William Jeffery\} and Becerra, \{Carlos Roberto\} and Piha-Paul, \{Sarina Anne\} and Peterson, \{Amy C.\} and Michelle Brown and James, \{Lee P.\} and Ming Zheng and Jieying Jiang and Georgia Kollia and Ailsa Swijter and Ascierto, \{Paolo Antonio\}",
note = "3058 Background: Blockade of the CTLA-4 pathway with ipilimumab (IPI) ± nivolumab (NIVO; anti-PD-1) is an effective treatment for a variety of cancers. To optimize the risk-benefit profile of CTLA-4-directed therapy, a Probody therapeutic technology platform (Pb-Tx, CytomX Therapeutics) was used to generate BMS-986249, a peptide-masked version of IPI that is unmasked by tumor-associated proteases.; 2020 ASCO Annual Meeting ; Conference date: 01-01-2020",
year = "2020",
doi = "10.1200/JCO.2020.38.15\_SUPPL.3058",
language = "American English",
}